Subcutaneous xenograft studies to verify target (MMP9) expression and evaluate therapy effects in different compartments of the tumour microenvironment demonstrated maximum gene expression changes within the tumour stroma by anti‐MMP9 antibody additionally supporting its antistromal activity in the PDAC tumour microenvironment. Here, MMP9 is linked to neoplasm.